Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Alzheimer's & Dementia

• Publication date

  2017-04-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.jalz.2016.12.003PMID 28188032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnosis and Classification of Diabetes Mellitus

  2019cited by this paper
• Harvard Aging Brain Study: Dataset and accessibility

  2017cited by this paper
• Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria

  2016influential reference
• Beta‐amyloid and cognitive decline in late middle age: Findings from the Wisconsin Registry for Alzheimer's Prevention study

  2016cited by this paper
• Dementia: The rising global tide of cognitive impairment

  2016cited by this paper
• Contributions of the Framingham Heart Study to the Epidemiology of Coronary Heart Disease.

  2016cited by this paper
• Application of Systems Theory in Longitudinal Studies on the Origin and Progression of Alzheimer's Disease.

  2016cited by this paper
• Toward a consensus recommendation for defining the asymptomatic‐preclinical phases of putative Alzheimer's disease?

  2016cited by this paper
• The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

  2016cited by this paper
• Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis.

  2015cited by this paper
• Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review

  2015cited by this paper
• Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease

  2015influential reference
• Reaction Time is a Marker of Early Cognitive and Behavioral Alterations in Pure Cerebral Small Vessel Disease

  2015cited by this paper
• Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease

  2015cited by this paper
• Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

  2015cited by this paper
• Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.

  2015cited by this paper
• The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

  2015cited by this paper
• Prediction of Alzheimer’s Disease Dementia: Data from the GuidAge Prevention Trial

  2015cited by this paper
• Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies

  2015cited by this paper
• Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of ageing.

  2015cited by this paper
• Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score

  2015cited by this paper
• The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective.

  2014cited by this paper
• Risk of dementia and mild cognitive impairment in older people with subjective memory complaints: meta‐analysis

  2014cited by this paper
• Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease

  2014cited by this paper
• Synergistic effect of β-amyloid and neurodegeneration on cognitive decline in clinically normal individuals.

  2014cited by this paper
• PART and SNAP

  2014cited by this paper
• The evolution of preclinical Alzheimer's disease: implications for prevention trials.

  2014cited by this paper
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Review - Part of the Special Issue: Alzheimer's Disease - Amyloid, Tau and Beyond Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

  2014cited by this paper
• Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.

  2014cited by this paper
• Optimizing Patient Care and Research: The Amsterdam Dementia Cohort

  2014cited by this paper
• Compensatory mechanisms in higher-educated subjects with Alzheimer's disease: a study of 20 years of cognitive decline.

  2014cited by this paper
• An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease

  2014cited by this paper
• A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease

  2014influential reference
• The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

  2014cited by this paper
• Unrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging

  2014cited by this paper
• The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.

  2014cited by this paper
• Cerebrospinal fluid β‐amyloid and phospho‐tau biomarker interactions affecting brain structure in preclinical Alzheimer disease

  2014cited by this paper
• The A4 Study: Stopping AD Before Symptoms Begin?

  2014cited by this paper
• Preclinical AD predicts decline in memory and executive functions in subjective complaints

  2013cited by this paper
• Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

  2013cited by this paper
• Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.

  2012cited by this paper
• Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

  2012cited by this paper
• [18F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies

  2012cited by this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cited by this paper
• Subjective cognitive complaints and amyloid burden in cognitively normal older individuals.

  2012cited by this paper
• Clinical and biomarker changes in dominantly inherited Alzheimer's disease.

  2012cited by this paper
• Preclinical AD Workgroup staging: pathological correlates and potential challenges.

  2012cited by this paper
• Indicators of amyloid burden in a population-based study of cognitively normal elderly

  2012cited by this paper
• Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.

  2011cited by this paper
• Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

  2011influential reference
• Use of florbetapir-PET for imaging beta-amyloid pathology.

  2011cited by this paper
• APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

  2010cited by this paper
• Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives

  2010cited by this paper
• The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans

  2010cited by this paper
• The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

  2009cited by this paper
• Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease.

  2009cited by this paper
• The Alzheimer's Disease Centers' Uniform Data Set (UDS): The Neuropsychologic Test Battery

  2009cited by this paper
• The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

  2008cited by this paper
• Effect of parental family history of Alzheimer's disease on serial position profiles

  2008cited by this paper
• The Mayo Clinic Study of Aging: Design and Sampling, Participation, Baseline Measures and Sample Characteristics

  2008cited by this paper
• Prodromal Alzheimer's disease: Successive emergence of the clinical symptoms

  2008cited by this paper
• Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria.

  2007cited by this paper
• Postmenopausal Estrogen Therapy and Alzheimer Disease: Overall Negative Findings

  2006cited by this paper
• Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI

  2006cited by this paper
• Effects of apolipoprotein E genotype on spatial attention, working memory, and their interaction in healthy, middle-aged adults: results From the National Institute of Mental Health's BIOCARD study.

  2005cited by this paper
• Middle-Aged Children of Persons With Alzheimer’s Disease: APOE Genotypes and Cognitive Function in the Wisconsin Registry for Alzheimer’s Prevention

  2005cited by this paper
• Available from:

  2002cited by this paper
• Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype.

  1998cited by this paper
• Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study.

  1996cited by this paper
• A quantitative histological study of early clinical and preclinical Alzheimer's disease

  1990cited by this paper
• Large amounts of neocortical βA4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person

  1990cited by this paper

• Role of Objective and Subjective Cognitive Status on the Driving Habits of Older Canadians: A COMPASS-ND Study.

  2026cites this paper
• What is the psychological and cognitive impact of returning Alzheimer disease dementia research results to healthy research participants? a delayed-start randomised clinical trial protocol for the WeSHARE study (Washington University study of having Alzheimer disease research results explained)

  2026cites this paper
• Risk of new-onset dementia following COVID-19 infection: a systematic review and meta-analysis.

  2025cites this paper
• Masitinib attenuates neuropathological changes in acrolein-induced sAD mouse model via NF-κB/NLRP3/Caspase-1 signaling pathway.

  2025cites this paper
• Associations Between B Vitamin Interactions with Polyunsaturated Fatty Acids and Cognitive Function Among Cognitively Healthy Older People as Modified by Amyloid Status and Sex

  2025cites this paper
• Unraveling the Tau Puzzle: A Brief Discussion on Biomarkers in Alzheimer’s Disease

  2024cites this paper
• Cross talk about the role of Neuropeptide Y in CNS disorders and diseases.

  2023cites this paper
• Acetylated tau exacerbates learning and memory impairment by disturbing with mitochondrial homeostasis.

  2023cites this paper
• Subjective cognitive decline and cerebral-cognitive reserve in late age

  2023cites this paper
• Insulin‐like growth factor‐2 is a promising candidate for the treatment and prevention of Alzheimer's disease

  2023cites this paper
• Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD

  2023cites this paper
• Episodic Memory Impairment Mediates the Loss of Awareness in Mild Cognitive Impairment

  2022cites this paper
• A combination of midlife diabetes mellitus and the apolipoprotein E ε4 allele increase risk for cognitive decline

  2022cites this paper
• Subtle Cognitive Deficits Are Associated with Amyloid-β Positivity, but Not Severity of Self-Reported Decline: Results from the CoSCo Study

  2022cites this paper
• Acrolein, an endogenous aldehyde induces Alzheimer's disease-like pathologies in mice: A new sporadic AD animal model.

  2021cites this paper
• Linguistic features and automatic classifiers for identifying mild cognitive impairment and dementia

  2021cites this paper
• The oxidatively damaged DNA and amyloid-β oligomer hypothesis of Alzheimer's disease?

  2021cites this paper
• Impact of Cardiovascular Risk Factors in Adolescence, Young Adulthood, and Midlife on Late-life Cognition: Study of Healthy Aging in African Americans (STAR).

  2021cites this paper
• A machine learning approach to screen for preclinical Alzheimer's disease.

  2021cites this paper
• Validity Evidence for the Research Category, “Cognitively Unimpaired – Declining,” as a Risk Marker for Mild Cognitive Impairment and Alzheimer’s Disease

  2021cites this paper
• Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A

  2021cites this paper
• Early diagnosis of Alzheimer’s disease: The role of biomarkers including advanced EEG signal analysis. An I.F.C.N.-sponsored panel of Experts

  2020cites this paper
• The meta-memory ratio: a new cohort-independent way to measure cognitive awareness in asymptomatic individuals at risk for Alzheimer’s disease

  2020cites this paper
• The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease

  2020cites this paper
• Downregulated Platelet miR-1233-5p in Patients with Alzheimer’s Pathologic Change with Mild Cognitive Impairment is Associated with Aβ-Induced Platelet Activation via P-Selectin

  2020cites this paper
• Environmental and Cognitive Enrichment in Childhood as Protective Factors in the Adult and Aging Brain

  2020cites this paper
• Identification of Earlier Biomarkers for Alzheimer’s Disease: A Multimodal Neuroimaging Study of Individuals with Subjective Cognitive Decline

  2020cites this paper
• The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders

  2020cites this paper
• A multilevel view of the development of Alzheimer's Disease.

  2020cites this paper
• Towards the Speech Features of Mild Cognitive Impairment: Universal Evidence from Structured and Unstructured Connected Speech of Chinese

  2019cites this paper
• Blood acetylcholinesterase level is a potential biomarker for the early detection of cerebral amyloid deposition in cognitively normal individuals.

  2019cites this paper
• Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network.

  2019cites this paper
• Prevalence and risk of progression of preclinical Alzheimer’s disease stages: a systematic review and meta-analysis

  2019cites this paper
• High Selectivity and Sensitivity of Oligomeric p-Phenylene Ethynylenes for Detecting Fibrillar and Prefibrillar Amyloid Protein Aggregates.

  2019cites this paper
• Reduction of recruitment costs in preclinical AD trials: validation of automatic pre-screening algorithm for brain amyloidosis

  2019cites this paper
• Cerebrospinal fluid from Alzheimer’s disease patients promotes tau aggregation in transgenic mice

  2019cites this paper
• Biomarkers for Alzheimer´s disease.

  2019cites this paper
• Gray Matter Densities in Limbic Areas and APOE4 Independently Predict Cognitive Decline in Normal Brain Aging

  2019cites this paper
• Which Episodic Memory Performance is Associated with Alzheimer’s Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD)

  2019cites this paper
• Subcortical amyloid relates to cortical morphology in cognitively normal individuals

  2019cites this paper
• Development of novel theranostic agents for in vivo amyloid imaging and protective effects on human neuroblastoma cells.

  2019cites this paper
• Biomarker-Based Signature of Alzheimer’s Disease in Pre-MCI Individuals

  2019cites this paper
• Aiginition Longitudinal Biomarker Investigation Of Neurodegeneration (ALBION): study design, cohort description, and preliminary data

  2019cites this paper
• Case report: a giant arachnoid cyst masking Alzheimer’s disease

  2019cites this paper
• Selective decline of neurotrophin and neurotrophin receptor genes within CA1 pyramidal neurons and hippocampus proper: Correlation with cognitive performance and neuropathology in mild cognitive impairment and Alzheimer's disease

  2019cites this paper
• The influence of life course vascular risk on brain pathologies and cognition in later life - a neuroimaging study of the British 1946 birth cohort

  2019cites this paper
• Elevated Plasma microRNA-206 Levels Predict Cognitive Decline and Progression to Dementia from Mild Cognitive Impairment

  2019cites this paper
• Design of data driven decision support systems for the early detection of subjects at risk to develop Alzheimer's disease. (Création de systèmes d'aide à la décision pour la détection précoce de sujets à risque de développer la maladie d'Alzheimer)

  2019cites this paper
• Characterization of phospholipids from Pacific saury ( Cololabis saira ) viscera and their neuroprotective activity

  2018cites this paper
• Speech Analysis by Natural Language Processing Techniques: A Possible Tool for Very Early Detection of Cognitive Decline?

  2018cites this paper
• Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ1–42 and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

  2018cites this paper
• Telephone-based Dementia Screening I: Automated Semantic Verbal Fluency Assessment

  2018cites this paper
• Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?

  2018cites this paper
• Prodromal Alzheimer’s Disease Demonstrates Increased Errors at a Simple and Automated Anti-Saccade Task

  2018cites this paper
• Biomarkers for Alzheimer’s Disease Drug Development

  2018cites this paper
• Neural correlates of episodic memory in the Memento cohort

  2018cites this paper
• Asymmetry of Hippocampus and Amygdala Defect in Subjective Cognitive Decline Among the Community Dwelling Chinese

  2018cites this paper
• Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.

  2018cites this paper
• Oxidant/Antioxidant Imbalance in Alzheimer's Disease: Therapeutic and Diagnostic Prospects

  2018cites this paper
• A Novel Therapeutic Approach to Treat Alzheimer’s Disease by Neurotrophic Support During the Period of Synaptic Compensation

  2018cites this paper
• Systems Biology Methods for Alzheimer's Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials.

  2018cites this paper
• Cognitive and neuroimaging features and brain β -amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study

  2018cites this paper
• Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics

  2017cites this paper
• The Emergence of a New Conceptual Framework for Alzheimer’s Disease

  2017cites this paper
• Physical Activity in Preventing Alzheimer’s Disease and Cognitive Decline: A Narrative Review

  2017cites this paper
• BACE1 inhibition by microdose lithium formulation NP03 rescues memory loss and early stage amyloid neuropathology

  2017cites this paper
• CRISPR/Cas9-Correctable mutation-related molecular and physiological phenotypes in iPSC-derived Alzheimer’s PSEN2N141I neurons

  2017cites this paper
• Neurotrophic factors in Alzheimer's and Parkinson's diseases: implications for pathogenesis and therapy

  2017cites this paper
• СТАРЕНИЕ МОЗГА. КОГНИТИВНЫЙ КОНТИНУУМ: КОГНИТИВНАЯ НОРМА – СУБЪЕКТИВНОЕ КОГНИТИВНОЕ СНИЖЕНИЕ

  year unknowncites this paper